Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

    • athos77@kbin.social
      link
      fedilink
      arrow-up
      60
      arrow-down
      4
      ·
      1 year ago

      It has an 89% efficacy rate in reducing hospitalization and death among the unvaccinated. I’m sorry that’s not “good enough” for you.

      • thepianistfroggollum@lemmynsfw.com
        link
        fedilink
        English
        arrow-up
        5
        arrow-down
        18
        ·
        1 year ago

        I’m just going off the information that my health care provider gave me. She said they only use it on high risk individuals because it’s not as effective as claimed.

        • superguy@lemm.ee
          link
          fedilink
          arrow-up
          1
          arrow-down
          1
          ·
          1 year ago

          Might want to find a new health care provider.

          She may be taking you for a ride.

    • KevonLooney@lemm.ee
      link
      fedilink
      arrow-up
      28
      arrow-down
      2
      ·
      1 year ago

      It does work, amazingly. I had Covid a few times and took Paxlovid the last time. It works better than any drug I’ve taken. After taking the first dose, there were no more Covid symptoms within 4-6 hours.

      The problem with Paxlovid (besides the cost) is that it gives you a new set of side effects: weird joint and muscle pain, a metallic taste in the mouth, etc. They’re better than Covid though. And it won’t kill you.

      • thepianistfroggollum@lemmynsfw.com
        link
        fedilink
        English
        arrow-up
        5
        arrow-down
        20
        ·
        1 year ago

        Just because it worked for you doesn’t mean that the effectiveness in their trials represents real world numbers. I’m not pulling this out of my ass, I was told this by a medical professional.

        • KevonLooney@lemm.ee
          link
          fedilink
          arrow-up
          16
          arrow-down
          2
          ·
          1 year ago

          There are many types of “medical professionals”. Only a vast minority actually read and interpret trial data.

          I’m going to trust my direct experience with the drug (I know it works) and real world studies like below.

          Conclusions: This study suggests that in the era of Omicron and in real-life settings, Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality.

          https://pubmed.ncbi.nlm.nih.gov/35653428/

          • SoleInvictus@lemmy.world
            link
            fedilink
            arrow-up
            7
            arrow-down
            4
            ·
            1 year ago

            Excuse me, that study only examined 140,219 patients. You’ll need WAY more, at least one million, to argue against the anecdotal opinion of a random, unspecified ‘medical professional’.

            /s so hard

            • thepianistfroggollum@lemmynsfw.com
              link
              fedilink
              English
              arrow-up
              2
              arrow-down
              5
              ·
              1 year ago

              Only 2.6% of the sample were given paxlovid, and they didn’t control for vaccination status.

              Also, it only covered 1 month nearly 2 years ago in a single country, and the virus has mutated several times since then.

              • SoleInvictus@lemmy.world
                link
                fedilink
                arrow-up
                1
                ·
                1 year ago

                The best part about having a background in statistics is watching people who don’t understand statistics try to explain why the math that doesn’t support their point actually does, somehow.

              • Muddybulldog@mylemmy.win
                link
                fedilink
                English
                arrow-up
                1
                ·
                1 year ago

                Paxlovid is a 3CL protease inhibitor. It modifies the primary enzyme that is common across all cornavirus.

          • FontMasterFlex@lemmy.world
            link
            fedilink
            arrow-up
            3
            arrow-down
            2
            ·
            1 year ago

            dude’s not saying it doesn’t work. he’s saying it doesn’t work as well as advertised. that perhaps doesn’t mean it’s only 50% effective for 100% people. perhaps it’s 100% effective for 20% of people. Think dude.

          • thepianistfroggollum@lemmynsfw.com
            link
            fedilink
            English
            arrow-up
            2
            arrow-down
            3
            ·
            1 year ago

            Ah, that was the era of omicron. We’re over 21 months and several variants past that now, and I was given the information about paxlovid last week.

            Also, that study only covers a single month in Israel in 2022 and only 2.6% of the sample was given paxlovid.

        • superguy@lemm.ee
          link
          fedilink
          arrow-up
          1
          arrow-down
          2
          ·
          1 year ago

          I was told this by a medical professional.

          What about all the medical professionals that disagree with your medical professional?

          This is why people like you should keep quiet on matters they know nothing about. If you want to understand something, you have to research it yourself.